See the announcement on PR Newswire

“The team at Saccharo has identified a novel druggable target of great potential and we are honored to be working with them to identify candidate antibodies for clinical development,” commented Garren Hilow, Chief Business Officer of Abveris. “By pairing best-in-class discovery tools with our team of impassioned scientists, we believe that we offer Saccharo the best chance of success in discovering and optimizing the biologic they require for clinical advancement.”

"Saccharo is delighted to be working with Abveris. We see Abveris’s scientists, experience, skills and technology platforms as offering the best potential for success,” said Sherry Martin-Moe, PhD, President/CEO and Co-Founder of Saccharo. “Importantly, they have been real partners in understanding the science and developing a sound strategy to produce the best possible antibodies for Saccharo to take to the clinic.”

See the announcement on PR Newswire

"The Immunitas team is uniquely positioned to identify novel therapeutic oncology targets using their innovative single cell genomics-based techniques. Pairing the Immunitas platform with efficient discovery of highly diverse panels of antibodies will result in the rapid identification of therapeutic-quality antibodies," commented Tracey Mullen, CEO of Abveris. "Our function-forward approach to antibody discovery will enable Abveris to deliver fully validated drug candidates in accelerated timelines. Ultimately, the synergy between the two platforms will result in faster delivery of targeted therapies to the patients who need them."    

"We are excited to collaborate with Abveris to accelerate the pace of discovery for some of our new antibody therapeutics," said Jeff Goldberg, CEO of Immunitas. "Our platform rapidly generates and validates new targets for treating challenging cancers. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations."

 

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Find additional information about Abveris at www.ABVERIS.com.

 

Contact for Abveris:

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

When a leader has the innate ability to help those around them become better, stronger all while focusing on the future, those abilities are rewarded.

That is why, effective today, Tracey Mullen will take over as Chief Executive Officer of Abveris. This change allows me to focus more on strategic partnerships and business development as Chief Business Officer. This decision was entirely my -own and, as the primary business owner of Abveris, a choice I believe is the right direction for our company.

During Tracey’s tenure at Abveris she has been responsible for increasing our average monthly revenue by 160%, more than doubling our company headcount, and co-leading the implementation of the Beacon B cell screening platform. A native of Connecticut, she earned her Bachelor’s Degree in Chemical-Biological Engineering from Massachusetts Institute of Technology (MIT), and her Executive Masters of Business Administration from Quantic School of Business and Technology.

Abveris is a scientific company and should be led by an elite scientist. With a strong focus on cutting-edge science and engineering, we at Abveris have the ability to change the future of medicine. We are now on a path to ensure this is our legacy. As we move out of the startup stage it is time for a new leader who has the skills I deem most valuable for our future: scientific knowledge, operational excellence, and courage.

Tracey is the most capable, talented, courageous and emotionally intelligent professional I have ever had the opportunity to know. She has earned the respect of everyone on our team and every one of our partners.  She is one of those rare leaders who makes everyone around her stronger and better — the rising tide that lifts all boats, not just a select few.

She is a glowing example of the next generation of leadership: a combination of subject matter expertise and sharp business acumen. There is a significant yet rare advantage in a leader like Tracey, who possesses an extensive understanding of our industry’s business operations as well as the intricate, technical details of our company’s work on the front lines.

I believe that a CEO should be the personification of her company’s brand. Tracey is Abveris personified: smart, hardworking, science-forward, deeply committed to success and fiercely competitive. I can’t think of a better embodiment of our premium, elite, yet approachable brand. Abveris has worked for years to hone the right brand, in the right market, with the right offering at the right time. Now that we have the right leader for the next phase of our company growth, we will move with more precision toward the opportunities that await us. 

Our business is, and has always been, to make quality biologic drugs. The antibodies we deliver will help cure disease and increase the quality of life globally. It is imperative that we continue to push ourselves as an organization to do the best job we possibly can so we can help make the world a better, healthier place. With Tracey making organization-wide decisions, Abveris will continue successfully fulfilling our mission to deliver the next generation of life-saving therapies.

In health and to our future,

Garren Hilow

Chief Business Officer, Creator, Owner

Made by mAb scientists, for mAb scientists

BEST ENJOYED AFTER A LONG DAY IN THE LAB

We teamed up with our neighbors at Castle Island Brewery to bring you specialty beers that mAb scientists are sure to love! Introducing mAb Scientist IPA and Six Pack mAbs Lager. Our team designed some hilarious labels and the Castle Island team came through with some delicious lager and IPA options. 

We'll be sending out cases of beer to our partners, but we also recognize many of you are working from home right now. Click below to provide your address information for us to send you some free brews! 

mAb Scientist IPA: OUR FLAGSHIP BEER

This beer is smooth but punchy; balanced yet intense. Despite the colossal amount of hops crammed into this beer, it’s still remarkably approachable for pros and rookies alike!

Our team held a naming competition for our flagship beer. After a close vote with many great names in the running, mAbScientist IPA rose to victory.  You may be asking: why does she have antibodies for hands? Fun fact: our monthly all-hands meeting is called "Monthly mAbs For Hands" after our all hands on approach to antibody discovery. 

Six Pack mAbs Lager: A SUMMER SPECIAL

Whether you’re catching the game, conquering the trail, or walking in the door from your commute home, sometimes you just need a beer. Brewed distinctively for the everyday, this classic American Lager is light and crisp, and will have you reaching for another sip. So kick your feet up, breathe easy, and crack into a can of this liquid bliss."

This beer label speaks for itself. We all love the beach this time of the year, and we love showing off the muscles we've built while sitting on our butts all day at the biosafety cabinets. 

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Additional information about Abveris is available at www.ABVERIS.com.

About Castle Island Brewery: 

Castle Island Brewery is based out of Norwood, Ma and can be found in fridges across New England. Their tasteful, easy to drink selection of beers is perfect for all beer drinkers from the beginner to the beer expert. Castle Island has their main staples, including the Keeper, American Lager, White Ale, and CandlePin but they are always making new exciting beers to keep up with their loyal customers evolving tastes! Check out more on their website: www.castleislandbeer.com

Click here to see the press release on BusinessWire.

Canton, MA, USA – Abveris, Inc. (“Abveris”) announced today that it has entered into an antibody discovery partnership with Nkarta, Inc. (“Nkarta”) for the discovery of fully-human monoclonal antibodies to support the advancement of Nkarta’s novel cell-based therapeutics. Under the terms of the agreement, Abveris will apply its next-generation B cell screening platform (powered by the Berkeley Lights Beacon^®) to rapidly discover fully human monoclonal antibodies using the Trianni Mouse^®, an industry-leading transgenic mouse R&D platform. 

“We have worked with the Trianni Mouse across several therapeutic antibody programs and have been impressed with the success of these campaigns,” commented Colby Souders, Ph.D., Chief Scientific Officer of Abveris. “Abveris is uniquely positioned to dramatically shorten therapeutic discovery timelines while enhancing candidate selection by pairing optimized immunization methods in the Trianni Mouse with high-resolution single B cell screening enabled by the Berkeley Lights Beacon.”    

“We believe this partnership brings together powerful discovery technologies with the potential for accelerating Nkarta’s pipeline of natural killer cell therapy candidates,” said James Trager, Ph.D., Chief Scientific Officer of Nkarta. “We look forward to working closely with the Abveris team on the identification of targeted antibodies ideally suited for our cell engineering and manufacturing platform.”

“The Nkarta team is situated to redefine the way we think about cell therapies, and we are delighted to be working with their team of impassioned scientists,” added Tracey Mullen, MBA, Chief Operating Officer of Abveris. “This partnership highlights our continued commitment to working with organizations leveraging antibody therapeutics in innovative and transformative ways.” 

"We at Trianni are thrilled that the partnership of Abveris and Nkarta includes the use of the Trianni Mice. It is gratifying to contribute to the program of creating novel antibody therapeutics," said Matthias Wabl, Ph.D., Chief Executive Officer of Trianni, Inc.

About Abveris: 

Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Additional information about Abveris is available at www.ABVERIS.com.

About Trianni, Inc: 

Trianni, Inc. is a privately held biotech company specializing in antibody discovery technology. Trianni’s lead technology, the Trianni Mouse®, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. Trianni’s transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology. The company is headquartered in San Francisco, CA. Additional information about Trianni is available through its corporate website, www.TRIANNI.com.

Contact for Abveris:

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

Contact for Trianni:

Elizabeth Tran

Marketing manager

elizabeth.tran@trianni.com

(415) 231-0257

On-cell receptor functionality is a crucial threshold for drug development. By leveraging high content screening in antibody discovery workflows, you are able to improve the likelihood of campaign success at early stages of development. Join us for our webinar hosted by our COO Tracey Mullen and our friends at Sartorius, where Tracey will walk through a case study outlining how we incorporate this technology for antibody discovery projects targeting cell surface receptors. 

Tuesday, April 28, 2020, 11 am EDT

Overview:

The use of monoclonal antibody-based therapeutics to target and treat cancer is considered to be one of the most successful therapeutic strategy within the oncology field to date. Specific cell surface antigen recognition is paramount to the success of these drugs, necessitating high resolution, early stage characterization of lead antibody drug candidates prior to preclinical development. In this webinar, Tracey Mullen, COO of Abveris, will review an antibody discovery campaign targeting a cell surface receptor implicated in cancer. Methods for immunization, antibody discovery, and subsequent functional characterization will be detailed.

Who Should Attend:

• Antibody discovery scientists and researchers engaged in therapeutic drug discovery in oncology indications

• Anyone interested in learning more about incorporating high-throughput flow cytometry analysis into early stage research and development

Speakers:

Tracey Mullen, Chief Operating Officer, Abveris

How can we access greater antibody diversity through the plasma B cell repertoire? How can we down-select lead candidates in 1 day? Join Abveris and Berkeley Lights for an exclusive webinar opportunity to learn how we're redefining the boundaries of antibody discovery with the Berkeley Lights Beacon platform.

Tuesday, April 14, 2020, 11 am EDT

Overview:

As the complexity of therapeutic targets continues to evolve, more efficient and predictive identification of pertinent antibody candidates becomes increasingly valuable. Incorporating state-of-the-art, high-resolution discovery and antibody characterization tools like the Berkeley Lights platform into discovery workflows enables rapid and reliable selection of lead candidates more effectively than traditional techniques. Elucidating function early during screening and development can enhance candidate triage, as opposed to relying on brute-force methods to characterize large panels containing primarily non-functional clones. Optimization of the discovery platform using the Beacon instrument and case studies will be outlined.

Speakers:

Colby A. Souders, Ph.D., Chief Scientific Officer, Abveris

Canton, MA, USA and Newark, DE, USA, April 8, 2020 - Abveris, Inc., a leader in contract research antibody discovery, today announced the extension of a strategic collaboration with ACROBiosystems, an internationally recognized manufacturer of recombinant proteins.

Under the terms of the agreement, the companies will leverage their core technologies to construct streamlined offerings to accelerate the pace of antibody discovery research.

By the terms of the agreement, over 1600 recombinant proteins for biologic drug discovery and development available in the ACROBiosystems catalog will be made available to Abveris customers to facilitate rapid initiation of antibody discovery projects.

"Our collaboration with ACROBiosystems is a highly valuable resource for Abveris and all of our partner companies,” commented Ryan Kelly, Director of Business Development at Abveris. "Our access to ACRO’s high-quality “off-the-shelf” reagents allows us to identify diverse, high affinity antibody clones in as little as one month total.”

“We are delighted to collaborate with Abveris, who shows their expertise in therapeutic antibody development. Their special DiversimAb^TM platform and single B cell screening platform speed up the antibody generation process while providing maximum diversity and affinity of the antibody candidates. It delivers additional benefits and comforts to scientists with using ACRO’s high-quality reagents and Abveris’s technologies as a combination,” commented Simin He, Marketing Manager of ACROBiosystems.

About Abveris: 

Abveris is a Boston-area specialty antibody discovery contract research organization located in Canton, Massachusetts, USA. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.

About ACROBiosystems: 

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process. Check out more details at: www.acrobiosystems.com/.

Contact for Abveris:

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

Contact for ACROBiosystems:

Grace Wang

Marketing Specialist

Grace.wang@acrobiosystems.com

408-320-2195

Abveris, Inc. 

March 18, 2020

RE: Staying Open for Science, COVID Response

To Our Valued Customers & Partners,

The COVID outbreak has caused significant disruptions to the science community worldwide, and your ongoing antibody discovery projects shouldn’t cause additional stress. Abveris will remain open for business and continue to provide contract research services during the state of emergency even if a "shelter-in-place" order is called. 

Abveris has multiple ongoing projects that directly contribute to drug development efforts for underserved diseases and indications (including COVID-19 and multiple other viral agents). Our end-to-end antibody discovery services are fully operational and we’re accepting new hybridoma and B cell screening discovery projects. Are you delaying your discovery work because of COVID-related antigen production delays? We can help.

Schedule 15 minutes with us today to discuss your project.

We are closely monitoring communications from the Massachusetts State and Federal Governments regarding measures to prevent the spread of the virus. Abveris has implemented mandatory work-from-home policies for non-essential staff, and employee schedules have been adjusted to promote social distancing. 

We welcome you to lean on us during these turbulent times. As always, we look forward to supporting your science.

Sincerely,

Garren Hilow

CEO of Abveris

Adversity has the effect of eliciting talents,

which in prosperous circumstances would have lain dormant

- Horace

Updated 3/6/20: Event cancelled due to concerns surrounding spread of COVID-19 virus. 

A note from the event organizers:

Thank you for your interest in our event, and we apologize that we must postpone the happy hour indefinitely due to concerns surrounding the spread of Covid-19 infection. 

We're proud to announce that we had over 100 attendees registered a week ahead of the event. When the time is right, we will announce a revised event date. 

Thursday | March 12 | 5:00-7:30 PM | Cambridge, MA

Open Bar & Free Appetizers

What is Brews & Biopharma?

A free happy hour for biopharma scientists.

An exclusive, relaxed event for biopharma scientists in the protein sciences. Finish your workday (and start your night) with us over casual drinks, appetizers, and networking.

Who is invited?

Scientists from our partner companies and their invited guests*

*We kindly ask you not to invite your professional recruiter or salesperson friends as your guests. Nobody likes to be pitched after work. Thank you for respecting our policy.